Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

USA - NASDAQ:TOI - US68236X1000 - Common Stock

4.75 USD
+0.14 (+3.04%)
Last: 10/24/2025, 8:00:01 PM
4.8 USD
+0.05 (+1.05%)
After Hours: 10/24/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TOI. TOI was compared to 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of TOI have multiple concerns. While showing a medium growth rate, TOI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
In the past 5 years TOI reported 4 times negative net income.
In the past 5 years TOI reported 4 times negative operating cash flow.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of TOI (-33.86%) is worse than 87.13% of its industry peers.
Industry RankSector Rank
ROA -33.86%
ROE N/A
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 15.02%, TOI is doing worse than 65.35% of the companies in the same industry.
In the last couple of years the Gross Margin of TOI has declined.
TOI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

1

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TOI has more shares outstanding
The number of shares outstanding for TOI has been increased compared to 5 years ago.
The debt/assets ratio for TOI is higher compared to a year ago.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.40, we must say that TOI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.40, TOI is not doing good in the industry: 67.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.4
ROIC/WACCN/A
WACC8.15%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.62 indicates that TOI should not have too much problems paying its short term obligations.
TOI's Current ratio of 1.62 is in line compared to the rest of the industry. TOI outperforms 56.44% of its industry peers.
TOI has a Quick Ratio of 1.37. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, TOI is in line with its industry, outperforming 52.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.37
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

TOI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.84%, which is quite good.
TOI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.53%.
TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.41% yearly.
EPS 1Y (TTM)13.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)17.53%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%21.53%

3.2 Future

Based on estimates for the next years, TOI will show a very strong growth in Earnings Per Share. The EPS will grow by 20.78% on average per year.
The Revenue is expected to grow by 17.15% on average over the next years. This is quite good.
EPS Next Y-26.98%
EPS Next 2Y13.91%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue Next Year14.33%
Revenue Next 2Y17.41%
Revenue Next 3Y17.15%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOI. In the last year negative earnings were reported.
Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

TOI's earnings are expected to grow with 20.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.91%
EPS Next 3Y20.78%

More info and screens

0

5. Dividend

5.1 Amount

TOI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (10/24/2025, 8:00:01 PM)

After market: 4.8 +0.05 (+1.05%)

4.75

+0.14 (+3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-13 2025-11-13
Inst Owners40.45%
Inst Owner Change-0.02%
Ins Owners3.51%
Ins Owner Change-55.36%
Market Cap444.13M
Revenue(TTM)424.38M
Net Income(TTM)-54115000
Analysts82.86
Price Target7.14 (50.32%)
Short Float %6%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.69%
EPS NQ rev (1m)5.56%
EPS NQ rev (3m)5.56%
EPS NY rev (1m)2.14%
EPS NY rev (3m)-233.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS4.54
BVpS-0.1
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.02%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score3
Asset Turnover2.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.06%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.37
Altman-Z 1.4
F-Score3
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y-26.98%
EPS Next 2Y13.91%
EPS Next 3Y20.78%
EPS Next 5YN/A
Revenue 1Y (TTM)17.53%
Revenue growth 3Y24.68%
Revenue growth 5Y20.41%
Sales Q2Q%21.53%
Revenue Next Year14.33%
Revenue Next 2Y17.41%
Revenue Next 3Y17.15%
Revenue Next 5YN/A
EBIT growth 1Y26.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.59%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLOGY INSTITUTE INC/THE / TOI FAQ

Can you provide the ChartMill fundamental rating for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a fundamental rating of 2 / 10 to TOI.


What is the valuation status for TOI stock?

ChartMill assigns a valuation rating of 0 / 10 to ONCOLOGY INSTITUTE INC/THE (TOI). This can be considered as Overvalued.


How profitable is ONCOLOGY INSTITUTE INC/THE (TOI) stock?

ONCOLOGY INSTITUTE INC/THE (TOI) has a profitability rating of 0 / 10.


What is the financial health of ONCOLOGY INSTITUTE INC/THE (TOI) stock?

The financial health rating of ONCOLOGY INSTITUTE INC/THE (TOI) is 1 / 10.